210 related articles for article (PubMed ID: 27492739)
1. Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study.
Valachis A; Garmo H; Weinman J; Fredriksson I; Ahlgren J; Sund M; Holmberg L
Breast Cancer Res Treat; 2016 Sep; 159(2):293-303. PubMed ID: 27492739
[TBL] [Abstract][Full Text] [Related]
2. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study.
Kelly CM; Juurlink DN; Gomes T; Duong-Hua M; Pritchard KI; Austin PC; Paszat LF
BMJ; 2010 Feb; 340():c693. PubMed ID: 20142325
[TBL] [Abstract][Full Text] [Related]
3. Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study.
Busby J; Mills K; Zhang SD; Liberante FG; Cardwell CR
Breast Cancer Res; 2018 Jan; 20(1):4. PubMed ID: 29351761
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen.
Lash TL; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Hamilton-Dutoit S; Garne JP; Ewertz M; Sørensen HT; Pedersen L
Acta Oncol; 2010 Apr; 49(3):305-12. PubMed ID: 20156115
[TBL] [Abstract][Full Text] [Related]
5. Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study.
Donneyong MM; Bykov K; Bosco-Levy P; Dong YH; Levin R; Gagne JJ
BMJ; 2016 Sep; 354():i5014. PubMed ID: 27694571
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.
Lash TL; Pedersen L; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Hamilton-Dutoit S; Garne JP; Ewertz M; Sørensen HT
Br J Cancer; 2008 Aug; 99(4):616-21. PubMed ID: 18665165
[TBL] [Abstract][Full Text] [Related]
7. Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: risk of breast cancer recurrence and mortality.
Cronin-Fenton D; Lash TL; Sørensen HT
Future Oncol; 2010 Jun; 6(6):877-80. PubMed ID: 20528223
[No Abstract] [Full Text] [Related]
8. Interaction of serotonin reuptake inhibitors with tamoxifen.
Andersohn F; Willich SN
BMJ; 2010 Feb; 340():c783. PubMed ID: 20142323
[No Abstract] [Full Text] [Related]
9. Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors.
Haque R; Shi J; Schottinger JE; Ahmed SA; Cheetham TC; Chung J; Avila C; Kleinman K; Habel LA; Fletcher SW; Kwan ML
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26631176
[TBL] [Abstract][Full Text] [Related]
10. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.
Dezentjé VO; van Blijderveen NJ; Gelderblom H; Putter H; van Herk-Sukel MP; Casparie MK; Egberts AC; Nortier JW; Guchelaar HJ
J Clin Oncol; 2010 May; 28(14):2423-9. PubMed ID: 20385997
[TBL] [Abstract][Full Text] [Related]
11. Adherence to adjuvant endocrine therapy: is it a factor for ethnic differences in breast cancer outcomes in New Zealand?
Seneviratne S; Campbell I; Scott N; Kuper-Hommel M; Kim B; Pillai A; Lawrenson R
Breast; 2015 Feb; 24(1):62-7. PubMed ID: 25486877
[TBL] [Abstract][Full Text] [Related]
12. The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors.
Hussaarts KGAM; Berger FA; Binkhorst L; Oomen-de Hoop E; van Leeuwen RWF; van Alphen RJ; Mathijssen-van Stein D; de Groot NMS; Mathijssen RHJ; van Gelder T
Pharm Res; 2019 Dec; 37(1):7. PubMed ID: 31845095
[TBL] [Abstract][Full Text] [Related]
13. [Patient safety with breast cancer and depression: Concomitant use of paroxetine and tamoxifen].
Muquebil Ali Al Shaban Rodríguez OW; Pérez Castro P; Estrada Alarcón N; Tuñón Gorgojo L
J Healthc Qual Res; 2019; 34(2):110-111. PubMed ID: 30686622
[No Abstract] [Full Text] [Related]
14. Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.
Binkhorst L; Mathijssen RH; van Herk-Sukel MP; Bannink M; Jager A; Wiemer EA; van Gelder T
Breast Cancer Res Treat; 2013 Jun; 139(3):923-9. PubMed ID: 23760858
[TBL] [Abstract][Full Text] [Related]
15. Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain.
Font R; Espinas JA; Barnadas A; Izquierdo A; Galceran J; Saladie F; Marcos-Gragera R; Torrent A; Manchon-Walsh P; Borras JM
Breast Cancer Res Treat; 2019 Jun; 175(3):733-740. PubMed ID: 30887164
[TBL] [Abstract][Full Text] [Related]
16. Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition.
Lehmann D; Nelsen J; Ramanath V; Newman N; Duggan D; Smith A
J Clin Pharmacol; 2004 Aug; 44(8):861-5. PubMed ID: 15286089
[TBL] [Abstract][Full Text] [Related]
17. Adherence to endocrine therapy including ovarian suppression: A large observational cohort study of US women with early breast cancer.
Reeder-Hayes KE; Mayer SE; Lund JL
Cancer; 2021 Apr; 127(8):1220-1227. PubMed ID: 33508140
[TBL] [Abstract][Full Text] [Related]
18. Adherence to endocrine therapy for breast cancer.
Chlebowski RT; Geller ML
Oncology; 2006; 71(1-2):1-9. PubMed ID: 17344666
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
Blanchette PS; Lam M; Richard L; Allen B; Shariff SZ; Vandenberg T; Pritchard KI; Chan KKW; Louie AV; Desautels D; Raphael J; Earle CC
Breast Cancer Res Treat; 2020 Jan; 179(1):217-227. PubMed ID: 31571072
[TBL] [Abstract][Full Text] [Related]
20. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Stearns V; Johnson MD; Rae JM; Morocho A; Novielli A; Bhargava P; Hayes DF; Desta Z; Flockhart DA
J Natl Cancer Inst; 2003 Dec; 95(23):1758-64. PubMed ID: 14652237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
